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ABSTRACT 
An abstract of the thesis of Rosemary Ann Lown for the Master of 
Science in Biology, presented May 18, 1994. 
Title: Investigations of Factors Affecting the Transcriptional 
Regulation of Herpes Simplex Virus Type 1 ~'Y (Leaky-Late) 
Genes. 
Herpes simplex virus type 1 (HSV-1) is a virus commonly 
causing cold sores in humans, however, virulent infections are known 
to produce debilitating encephalitis and death. 
HSV-1 transcription is carried out by the host cell RNA 
polymerase II in a tightly regulated temporal cascade. The first 
genes transcribed, the a genes, are activated in the absence of viral 
DNA synthesis. Transcription of the other temporal classes, the p, py, 
and y genes is dependent upon the protein products of the a genes 
for activation. 
The purpose of this study was to investigate the factors that 
contribute to this rigid regulation of HSV-1 transcription. This 
investigation sought to identify some of the cellular and viral 
transcription factors that activate transcription of genes of the later 
kinetic classes. Two separate approaches were utilized in these 
/ 
investigations. 1) In vitro transcription using a soluble, cell free 
system to study the transcriptional regulation of the VP5 gene, and 
2) DNA competition binding assays to identify and characterize the 
protein-DNA complexes resulting from interaction between the cis-
acting DNA sequences of the VP5 gene, other viral genes, and the 
proteins that bind to them. 
2 
Attempts at in vitro transcription of ~, ~y, and y genes were 
unsuccessful. Because these genes require a products for activation, 
it was necessary to prepare nuclear extracts from infected cells. 
However, HSV-1 contains endogenous RNase activities which are 
components of the biochemical machinery by which the virus directs 
host transcription to the synthesis of viral molecules. The uses of 
virus deficient in the host shut-off function and various drugs were 
unsuccessful. 
Previous work in the Millette laboratory demonstrated a 
sequence in the VP5 promoter that played a significant role in the up 
regulation of expression of that gene. DNA binding competition 
studies using a number of HSV-1 sequences exhibiting partial 
homology to this sequence demonstrated that these sequences all 
compete for the binding of the same protein factor. Similarly, a piece 
of the human immunodeficiency virus (HIV) exhibiting a seven base 
pair homology also exhibited weak competition. 
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CHAPTER I 
INTRODUCTION 
Viruses are simple, submicroscopic structures capable of 
infecting an enormous variety of organisms. These noncellular 
genetic elements characteristically have an extracellular form that 1s 
the infective phase of the virus. The basic simplicity of viruses 
makes them obligate parasites, requiring host cells to carry out 
replicative processes. 
Typical viral composition includes a nucleic acid genome and at 
most a few proteins contained within a proteinaceous capsid. These 
submicroscopic parasites have the capacity to invade a cell and alter 
normal processes in a matter of minutes. However, the mechanisms 
by which viruses commandeer and alter the usual host physiology is 
at best poorly understood. 
Investigating viral systems allows a researcher access to two 
levels of analysis: In addition to studying viruses themselves, it is 
possible for a researcher to utilize viruses to perturb the normal cell 
physiology without causing immediate cell death. Therefore it 
becomes possible to study normal cellular processes utilizing a viral 
parasite. 
Herpes simplex virus type 1 (HSV-1) is a common pathogen 
that afflicts humans. Most frequently HSV-1 infections result in cold 
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sores; however, these viruses are also known to cause severe, 
debilitating and frequently fatal encephalitis, blindness and 
disfiguring scarring. Once a productive infection is established, HSV-
1 enters the sensory neurons of the infected cells and produces a 
latent infection in the cell body of the compromised neuron. Once 
sustained, latent infections persist throughout the lifetime of the 
host. Latent infections can periodically give rise to a lytic infection in 
the epithelial cells innervated by the affected nerve. 
Virus Structure 
In comparison to cells, viruses are structurally relatively 
simple. All herpesviruses exhibit the same four basic anatomic 
elements: A membranous envelope, a tegument, a capsid and a core 
(figure 1 ). The herpesvirus envelope is derived from the inner 
lamella of the nuclear membrane in the host cell. This viral envelope 
is composed of lipids, proteins and the polyamines spermine and 
spermidine (22). Despite the cellular origin of the viral envelope, it 
is remarkable for its lack of host proteins. Instead, the membrane-
bound proteins found in the envelope are virally encoded 
glycoproteins. The mechanism by which the host cell nuclear 
envelope is modified to exclude normal host proteins and incorporate 
only viral proteins is not clear. The viral envelope glycoproteins are 
believed to be transported to the nuclear membrane via a process 
involving the Golgi apparatus. What is clearly understood is that 
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viral glycoproteins are the means by which a virus attaches itself to 
and enters a cell. 
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Fi2ure 1. Structure of herpes simplex virus type 1. The 
toroidal DNA genome is contained within an icosahedral capsid. 
The capsid is surrounded by tegument contained within the 
host derived envelope. Viral receptors protrude from the 
envelope layer. Legend: A. Envelope. B. Capsid. C. Viral 
DNA. D. Tegument. E. Glycoproteins. 
Separating the viral envelope from the underlying capsid is the 
amorphous tegument. The components of this structure have not 
been thoroughly defined. However, it is known that a number of 
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viral proteins are typically found in the tegument, particularly the 
transcription regulatory factors atrans-inducing factor (aTIF), ICP4, 
ICPO, ICP27, and the viral host shutoff (VHS) protein (52). 
Beneath the tegument, the proteinaceous capsid houses the 
genetic material. The capsid is icosahedral in shape, and consists of 
seven virally-encoded proteins. It has been observed that the actual 
protein composition of the capsid varies somewhat depending on 
whether or not the viral DNA has been packaged within it and 
whether or not it has been enveloped (52). Within the capsid, the 
DNA is toroidal. 
The genome of HSV-1 is a linear, double-stranded molecule of 
DNA approximately 150 kilobase pairs (kbp) in size. The G+C 
(guanine plus cytosine) content is high (68% - 69%). Structurally, the 
DNA appears to consist of two components, the long (L) and short (S) 
segments, covalently linked end-to-end (figure 2). Each component 
contains a length of unique DNA sequence wedged between regions 
of inverted repeats (IRs) designated ab and a'b' flanking the long 
sequence, and a'c' and ac flanking the short sequence. The umque 
long (UL) region has a length of approximately 108 kbp. The unique 
short (Us) sequence is 13 kbp in length. The long terminal repeats 
(TRL) and short terminal repeats (TRs) are roughly 9.2 kbp and 6.6 
kbp respectively. The IRs themselves contain elements that are 
highly conserved, but they can exhibit some variability with respect 
to the number of internal repeated elements. The region of covalent 
linkage between the L and S components is the so called hinge 
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region. During replication, the L and S components can invert 
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Fi~rnre 2. The genome of HSV-1 illustrating the elements of the 
long (L) and short (S) components. The inverted repeats ab 
and a'b' flank the L component, and a'c' and ac flank the S 
component. The hinge region is located between the a' 
inverted repeats. Modified from Fields and Knipe (52). 
Herpesvirus Replicative Cycle 
The HSV-1 replication cycle begins with the attachment of the 
virion to receptors located in the host cell membrane. Particularly, 
heparan sulfate proteoglycans are recognized in one of the initial 
binding events (68). This initial attachment requires either (or 
both) viral glycoprotein B (gB) or glycoprotein C (gC) (43, 52). The 
initial stage of penetration is dependent upon the viral glycoproteins 
gB, gC and gH:L. Penetration of the virus into the cell interior is 
accomplished by virally-directed fusion of the HSV-1 envelope and 
the cell membrane, a process that requires the viral glycoproteins gB 
and gD. Once fusion between the virion and the cell membrane has 
occurred, the viral nucleocapsid and tegument enters the cell 
cytoplasm. In the process of penetration, the viral envelope is 
removed. (52). 
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The next event in HSV-1 replication is the transport of the viral 
nucleocapsids to the nuclear membrane by a mechanism thought to 
involve the cellular cytoskeleton. Upon arriving at the nuclear pores, 
the viral DNA is released into the nucleoplasm (52). 
Following the initial viral infection, there is a rapid shut off of 
host macromolecule synthesis and a switch of the cellular machinery 
to the production of viral proteins. This conversion from cellular 
macromolecule synthesis to viral macromolecule synthesis occurs in 
several stages. First, host polypeptide synthesis is suppressed 
coincident with the disaggregation of the infected cell polyribosomes. 
This is followed by a subsequent degradation of host cell mRNAs. 
The onset of viral polypeptide synthesis is associated with the 
formation of new, viral-specific polyribosomes that have a size 
distribution that is different from that of the host (32, 61 ). The 
initial shut-off, the disaggregation of host polyribosomes, is mediated 
by a virion structural component that is carried into the host cell m 
the tegument of the virus, the VHS protein. This vhs function 
enables the virus to remove host mRNA from the pool of translatable 
message, thus aiding the virus in switching from host protein 
synthesis to virion protein synthesis (30, 31 ). Additionally, data 
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indicates that the vhs gene product facilitates the transition between 
regulatory classes by destroying a and B mRNAs (61). 
The complete degradation of host mRN A requires expression of 
viral genes and is a secondary phenomenon coded for by a viral gene 
of the B or y class. It can occur without the prior host shut off events. 
(The viral host protein shut off is not required for the production of 
viral progeny.[32]). 
The transcription of HSV-1 genes is a coordinately regulated 
process in which the several kinetic classes of genes are transcribed 
m a temporal cascade by the host RNA polymerase II (figure 3) (64, 
67). 
The a genes, the first kinetic class, consist of five genes ( aO, a4, 
a22, a27 and a47). These genes are transcribed in the absence of 
viral protein synthesis. As a group most of these genes map in the 
long and short repeat regions of the HSV-1 DNA molecule, with aO 
and a4 present in two copies per genome. Typically, the a genes 
encode transcription regulatory factors and are required for the 
synthesis of the polypeptide products of subsequent kinetic classes 
(52). 
Transcription of the a genes themselves is induced by the viral 
trans-activating protein, aTIF (VP16) (24, 25). As previously 
mentioned, a TIF is a constituent protein of the tegument. As such it 
is released from the virus after penetration into the cell. This 
protein is transported to the nucleus independently of the viral DNA 
and interacts, not with a cis-acting regulatory DNA sequence, but 
with a cellular transcription factor, OTF-1, which in turn binds 
da 
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Figure 3. The replicative cycle of HSV-1 (49). 
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to a specific site in the viral a promoter. This sequence, located less 
than 400 bp upstream from the cap site, is unique to and 
characteristic of a promoters. OTF-1 binding to this region initiates 
transcription of a genes (24, 25, 38, 39, 49). Expression of a 
polypeptides peaks two to four hours post infection. 
Viral DNA replication and nucleotide synthesis are the major 
events associated with B protein expression and require prior 
expression of a proteins. Some B products appear very early in 
9 
infection. These have been designated the B1 genes, and include the 
large subunit of the viral ribonucleotide reductase and the major 
DNA binding protein. However, unlike a genes, they require viral 
transcription factors for activation. The protein products of B genes 
are generally involved in nucleotide and viral nucleic acid 
metabolism and viral DNA replication, e.g., thymidine kinase (tk), 
ribonucleotide reductase and the viral DNA polymerase among others 
( 11, 28 ). Peak polypeptide production of B genes occurs five to seven 
hours following infection. 
Inclusion of viral genes in the third kinetic class, the y genes, is 
somewhat arbitrary. Although expression of the entire complement 
of these genes requires viral DNA synthesis, the py or 'YI genes of 
HSV-1 are expressed at low levels before DNA replication, and at 
high levels following DNA replication (11, 64 ). In contrast, the true 
late, y or 'Y2 genes, require prior DNA replication for their expression. 
The mechanism of activation of both is poorly understood. It is know 
that a genes are required for initial onset of P'Y and y transcription 
(8). However, it has been observed that viral DNA replication is 
required for maximum py and y. In cells in which HSV-1 replication 
has occurred, the mRN As and proteins for the py and y genes are 
among the most numerous. Many of the P'Y and y genes code for viral 
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structural proteins, e.g. the major capsid protein VP5, and a number 
of glycoproteins (gB, gC, and gD) (52, 55). 
Following transcription, the viral mRNAs are capped, 
methylated, polyadenylated and transported to the cytoplasm. 
Protein synthesis is carried out by the host translation apparatus, 
apparently on both free and endoplasmic reticulum-bound 
polyribosomes. Following translation and post-translational 
processing (splicing, glycosylation, etc.), again carried out by host 
enzymes, virion proteins are transported back into the nucleus for 
assembly into mature progeny virus. The mechanism by which the 
protein constituents of HSV-1 are transported has not been defined, 
but assembly seems to occur by a spontaneous process akin to that 
described for the large bacteriophages, e.g., T4 (52). 
Viral DNA replication is first detected about three hours post 
infection. Viral DNA isolated early after the onset of replication 
yields both linear branched and circular forms of DNA. Indications 
are, however, that late in replication, HSV-1 is copied via the rolling 
circle mechanism from three origins of replication. Two origins are 
contained within the inverted repeats of the S segment, and the third 
in the approximate center of the unique long (UL) region. It has 
been observed that deletion of one of the S origins and the L origin 
does not adversely affect the ability of the virus to replicate (51 ). 
Production of mature infectious viral particles takes place in 
the nucleus. Capsids are formed from the proteins previously 
transported into the nucleus from the cytoplasm. Genome lengths of 
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DNA are processed and packaged into the empty capsids. It has been 
observed that, late in infection, the nuclear envelope typically 
contains areas of thickened, concave or convex patches that contain 
virion proteins, and that viral envelopment occurs at these patches. 
The DNA-filled viral capsids attach to the modified areas of the inner 
lamella of the nuclear envelope and bud through, encasing in the 
inner membrane (figure 3). Enveloped capsids then pass into the 
endoplasmic reticulum and are ultimately conveyed into the 
extracellular space. Production of progeny virus necessarily results 
in the destruction of the host cell. 
Latency 
One of the most puzzling aspects of an HSV-1 infection is the 
phenomenon of latency, that is, the ability of the virus to assume a 
quiescent state in host sensory neurons. Once latency is established, 
the virus can remain dormant for years, only to erupt into a fully 
lytic infection following some physiological trigger. 
Like so many aspects of the herpesvirus life cycle, the events 
of latency are obscure. What is known is that HSV-1 enters the 
sensory neurons associated with the infected cells. The capsids are 
transported to the nuclei of the neurons in the trigeminal nerve. 
Studies on latently infected neurons reveal only one set of viral 
transcripts, designated LAT RNAs (for latency-associated transcripts), 
that accumulates abundantly in the nuclei. These are transcribed 
from the terminal repeat of the unique long region of the herpes 
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genome and are at least partially complementary to the 3' end of 
ICPO (63). The function of these latency RNAs is currently under 
intense investigation by many laboratories and their role in 
maintaining latent viral infections and possibly in viral reactivation 
to productive infection is still obscure. 
Once established, the HSV-1 latent infection remains 
throughout the life of the host. Reactivation of the virus can result 
either from some local stimulus to the infected nerve, such as mJury 
to the tissue, or a systemic stimulus, e.g., emotional stress, 
menstruation, etc. 
Structure of Eukaryotic Genes 
Regulation of transcription in eukaryotic systems is intricate 
and details are only slowly becoming understood. A generalized 
pattern of required DNA regulatory sequences has painstakingly 
been constructed by many researchers over the years. It is known 
that genes of multicellular organisms contain both upstream and 
downstream cis-acting sequences that bind a variety of trans-acting 
protein factors. 
Cis-acting sequences include the TAT A box, a TA-rich region 
located 30 base pairs (bp) upstream (-30) from the transcription 
start site. Proteins necessary for starting transcription of protein 
coding genes include transcription factor-HD (TFnD), now called TBP 
(for TAT A binding protein) and TFAs (for TBP-associated factors). 
RNA polymerase II and various accessory proteins (TFnB, TFnE, 
TFnF, and TFnA) are also required (34). 
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Additionally, activators are required to ensure normal 
transcription in many genes. These cis-acting sequences may include 
a CCAAT box which is generally found at or near -80 from the 
transcription start site. However, the CCAAT box can function at 
distances that vary with respect to the start site and it can function 
in either orientation. This regulatory sequence is bound by proteins 
that form heterodimers. Each protein contributing to the 
heterodimer weakly binds the CCAAT DNA alone, but strongly binds 
when dimerized. 
Other activators include upstream activating sequences (U AS) 
which are necessary for maximal transcription. Features common to 
UAS include a location near the gene and a 15 to 20 bp segment that 
is bound by protein. Additionally, in mammalian genes, these UAS 
are often present in multiple copies and frequently exhibit dyad 
symmetry. Examples include the GC boxes, regions containing the 
consensus sequence GGGCGG, usually found within 200 bp of the 
transcription start site. These are known to be bound by stimulatory 
protein 1 (Spl) (34). 
One last category of activators is the set of enhancers. These 
cis-acting sequences differ from other activators in that they can be 
separated by large distances from the start site and can be located 
either upstream or downstream. Otherwise, enhancers exhibit 
characteristics found in sequences in the promoter region (34 ). 
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Viral promoters must meet two disparate requirements. They 
must be similar enough to host promoters to allow the host 
transcription factors to recognize and transcribe the viral genes. 
However, the viral promoters must be sufficiently different from the 
host promoters to allow independent regulation of the viral genes. 
Both host and viral promoters contain cis-acting sequences that bind 
a number of host trans-acting factors: TAT A boxes, CCAAT boxes, 
Spl and NF-1 consensus sequences. The trans-acting elements 
include both cellular transcription proteins that interact with these 
sequences, as well as virally encoded proteins, i.e., a4. 
The Problem 
VP5 is the major capsid protein of HSV-1. Kinetically, it is a 
leaky-late (~y or yI) gene, and consequently requires a gene products 
for transactivation (10). The VP5 promoter is typical of eukaryotic 
genes in that many of the cis-acting sequences are present, including 
a TATA box, a CCAAT box, Spl boxes, and NF-1/CTF at -75. 
Additionally, a positive regulatory sequence in the non translated 
region of the VP5 leader is located 50 bp downstream ( +50) from the 
cap site (64). It has been well documented that viral regulatory 
factors are an absolute requirement for expression of VP5 ( 14 ). 
The polypeptide product of VP5 is not expressed significantly 
m the early stages of the HSV-1 replicative cycle, but is absolutely 
essential in high concentration late in infection to ensure the 
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production of large numbers of progeny virus. Therefore, the virus 
must have some mechanism by which this gene is up-regulated. 
In this context, the Millette laboratory has been working to 
elucidate some of the transcriptional controls involved in gene 
regulation. The goal has been to identify the cellular and viral 
transcription factors that up-regulate VP5 expression following virus 
infection 
As previously noted, in order to effectively direct the host 
transcription mechanism away from producing cell proteins toward 
generating the components required to produce progeny virus, HSV-
1 promoters must successfully mimic the promoters native to the 
cell. In effect, the viral promoters must compete for transcription 
factors with cell promoters. 
A great deal is known about the elements that combine to form 
eukaryotic promoters, and by implication and direct studies, about 
HSV-1 promoters as well. However, because a particular binding 
sequence is present in a viral promoter does not necessarily mean 
that it fulfills the same role in a virus that it does in a cell. That is, 
the "on" switch and modulation of viral gene expression may differ 
subtly from the conditions observed in host promoters. Because a 
sequence exists that may bind a protein factor does not mean that it 
plays a regulatory role. An assay to demonstrate regulatory 
significance is required. 
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In this thesis research, two separate experimental approaches 
were utilized to investigate regulation of this gene during the 
infectious cycle: 
1. Cell free in vitro transcription was utilized to study the 
transcriptional regulation of the VP5 gene. 
2. DNA binding competition studies were employed to identify 
and characterize the protein-DNA complexes resulting from 
interaction between the cis-acting sequences of the VP5 
gene, other viral genes and the proteins that bind to 
them. 
The goal of this research was to identify cis-acting DNA sequences 
and trans-acting protein factors that are involved in the regulation of 
leaky-late transcription. 
Cells and Viruses 
CHAPTER II 
MATERIALS AND METHODS 
HeLa cells (ATCC #CCL2), derived from a human cervical 
epithelioid carcinoma, (adenocarcinoma) were used for preparation 
of all nuclear extracts. HEp-2 cells (ATCC #CCL23), a human 
laryngeal epidermoid carcinoma cell line, were used for preparation 
of all viral stocks. Herpes simplex virus, type I, (HSV-1) KOS strain 
(wild type) and vhsl (mutant strain deficient in the virus host shut 
off of protein synthesis) were used in preparation of infected cell 
extracts. 
Preparation of Stock Virus 
Stock virus were prepared by infecting nearly confluent 
(approximately 85% confluent) HEp-2 cell roller bottle cultures m 
Dulbecco's Modified Eagle Medium (DME) plus 1 % inactivated calf 
serum (Gibco) at low multiplicity (0.02 plaque forming units [pfu] per 
cell). Viral harvest was done when cells exhibited cytopathic effects 
indicated by changes in cell morphology (i.e., rounding, loss of 
confluency ), typical of viral infection at approximately three days 
post infection. Harvest was accomplished by scraping the cells into 
the medium. The cells were pelleted by centrifugation at 4 ° C, 2000 x 
g for 10 minutes. The cells were disrupted on ice with the Bran sen 
Sonnifier W-350 in 15 second bursts for two minutes with the 
setting at two. Cell debris was removed by centrifugation for 30 
minutes at 2000 x g at 4 °C. The supernatant liquid containing the 
virus particles was stored at -70°C in DME containing10% heat 
inactivated fetal calf serum. 
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The viral titer was determined by plaque assay on Vero cells 
(ATCC #CCL81 ), African green monkey kidney cells, grown in 
monolayer cultures as described by Millette et al. ( 40). 
Preparation of Nuclear Extracts 
Nuclear extracts were prepared as described by Dignam, et al. 
(16) or Shapiro (57) except as follows. HeLa cells were grown in 
monolayer roller bottle cultures in DME plus 5% inactivated calf 
serum. Preparation of infected extracts was achieved by infecting 
monolayer cultures at a confluency of approximately 80% with HSV-
1 at a multiplicity of 10 pfu/cell. Cells were harvested at 
approximately eight hours post infection by rinsing the monolayers 
twice with ice cold phosphate buffered saline (PBS) and scraping into 
cold PBS. The cells were pelleted by centrifugation at 2000 x g for 
ten minutes at 4 °C. 
Cycloheximide reversed v hs 1 infected extracts were prepared 
as described by Dignam, et al. ( 16) or Shapiro (57). The infection 
protocol utilizing the drugs involved adding cycloheximide (final 
concentration of 50 µg/ml) was added to the medium one-half hour 
prior to infection. Virus was introduced at a multiplicity of ten 
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pfu/cell. One and one-half hours post infection, the infecting 
suspension was decanted and the cells were overlaid with DME plus 
1 % inactivated calf serum with cycloheximide, 50 µg/ml. Five and 
one-half hours after infection, actinomycin D was added to the 
medium at a final concentration of 5 µg/ml. Following a 30 minute 
incubation, the cycloheximide block was reversed with three washes 
of medium containing 5 µg/ml actinomycin D. Harvesting of the cells 
was carried out one and one-half hours following cycloheximide 
reversal. Nuclear extracts were prepared as previously described. 
DNA and Plasmids 
Plasmid DNA was prepared by the alkaline lysis procedure (4) 
with modifications as described in Sambrook et. al. (54). Briefly, this 
procedure consists of growing liquid cultures of E. coli containing the 
plasmid of interest with the appropriate antibiotic, i.e., ampicillin at a 
final concentration of 50 µg/ml. Plasmids were amplified in late log 
phase by adding chloramphenicol to a final concentration of 170 
µg/ml. Bacteria were harvested 12 to 16 hours post amplification by 
centrifugation at 4000 x g. Cells were resuspended in buffer 
containing 0.1 M NaCl, 10 mM Tris-Cl, and 1 mM EDTA. Cells were 
lysed with lysozyme (10 mg/ml in 10 mM Tris-Cl) followed by 0.2N 
NaOH in 10% SDS (sodium dodecyl sulfate). Following the addition 
3M potassium in 5M acetic acid to neutralize the alkaline NaOH/SDS, 
the chromosomal DNA and cell debris were removed by 
centrifugation. The supernatant liquid containing the plasmid DNA 
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was filtered through four layers of cheese cloth and plasmids were 
collected by isopropanol precipitation and purified by precipitation 
with PEG-8000. 
Fragments were isolated from restricted plasmids by the DEAE 
paper electroelution method (19). DNA fragments were labeled at 
the 3' ends by Kienow fill-in (54) using [a-32p]dCTP. 
Plasmid pKSBBO was made in this lab by the insertion of the 
2.24 kB BstEII-BamHI fragment of the BamZ fragment of HSV-1 into 
pBR322. This fragment contains the ICPO gene. Plasmids pSG22 
(23), pHSV106 (39), pVP5(-168)CAT (6), pVP5(-168)CATLl2 (10) and 
pJB3 (29), pRB122 (66), pHKg (1), pIMlO and pGTSa2 (33), pU3RIII 
and pU3RIII-167 (53) were either previously prepared in this 
laboratory or obtained from others. They are described in Table I. 
Enzymes 
Restriction endonucleases were purchased from Bethesda 
Research Labs, Inc. (BRL) or New England Biolabs, Inc. Restriction of 
DNA was carried out using the lOx reaction buffers provided by the 
manufacturers or the appropriate concentration of KGB buffers 
(54W). DNA was digested for two to four hours at 37° with three to 
four units enzyme per µg DNA. 
In Vitro Transcriptions 
In vitro transcriptions were performed as described in Dignam, 
et al. (16) and Shapiro (56) except [a-32P]CTP was used. Briefly, 
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Transcriptions were carried out in 50mM Tris HCl, pH 8, 10 mM to 12 
mM MgClz, 0.6 mM ATP, GTP and UTP, 1 mM CTP, 80 mM KCl, 200 
mM DTT (dithiothreitol), 50 µM [a-32p]CTP (10 µCi), 15 to 29 ng/µl 
DNA, and nuclear extract (75 µg/ml protein). The transcription 
mixture was incubated for 60 minutes at 30°C. RNA was purified by 
phenol-chloroform-isoamyl alcohol extraction and ethanol 
precipitation. The RNA pellets were dried under vacuum for 15 
minutes and denatured with glyoxal. Analysis of RNA was 
accomplished by gel electrophoresis for 600 volt-hours in a 1.6% 
,.. 
!~ 
agarose gel in phosphate buff er with recirculation as described by 
Beck and Millette (2). The gels were dried under vacuum and 
exposed to Fuji RX film for autoradiography at -80°C for 24 to 48 
hours. 
Gel Mobility Shift Assays 
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Gel mobility shift reaction mixtures contained 0.5 ng to 1.5 ng 
(5000 to 8000 cpm) DNA probe, 2.8 µg poly(dl-dC):poly(dl-dC) 
(Pharmacia), and nuclear extract (1.8 µg protein) mixed in a reaction 
buffer providing final concentrations of 6 mM Tris-HCl, pH 7 .9, 40 
mM KCl, 2 mM EDTA, 0.2 mM DTT (dithiothreitol), 8% (v/v) glycerol 
in a total volume of 25 µl. Following a 30 minute incubation at room 
temperature, 2 µl of 0.25% bromphenol blue was added and the 
samples were electrophoresed at 4 °C through polyacrylamide gels 
made with 4% acrylamide, 0.13% bisacrylamide in a Tris-borate 
buffer that was 25 mM Tris base, 25 mM boric acid, and 1 mM EDT A. 
Gels were vacuum dried and exposed to Fuji RX films with 
intensifying screens. 
DNA Competition Binding Assays 
The DNA competition binding assays were carried out under 
the same conditions specified for gel mobility shift assays except for 
the following. A 40-100 molar excess of unlabelled competitor DNA 
added to the reaction mix which was then incubated at room 
temperature for ten minutes prior to adding the radiolabelled probe. 
"" 
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Then 0.2 to 0.5 ng of DNA probe was mixed into the reaction mixture, 
and room temperature incubation continued for an additional 20 
minutes. The samples were then electrophoresed as described above 




I. USE OF AN IN VITRO TRANSCRIPTION SYSTEM TO STUDY HSV-1 ~'Y 
(y1) GENE TRANSCRIPTION 
It is possible to generate RN A from an isolated promoter 
sequence via in vitro transcription in a soluble cell free system ( 16, 
57). Using extracts prepared from cells not infected with HSV-1, it is 
expected that promoters from HSV-1 a genes would be readily 
transcribed. Because B and By genes require a products for 
expression, transcription from these promoters is not predicted 
under the same experimental conditions. 
A. Immediate Early (a) Genes. But Not Later Classes. Are Transcribed 
by a Nuclear Extract from Infected Cells. 
Before the regulation of VP5 transcription could be studied by 
in vitro assay, it was necessary to demonstrate that it is possible to 
generate RNA from HSV-1 promoter templates in soluble cell-free 
systems. This was accomplished by choosing promoters from the 
various kinetic classes and subjecting them to transcription with 
extracts prepared from uninfected HeLa cells by the Dignam protocol 
as described. The ICPO promoter (a gene) transcribed readily in the 
soluble cell-free extracts yielding a specific transcript of 1.4 kbp 
.I 
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(figure 4, lane 4). However, promoters from the later kinetic classes 
transcribed poorly and, at most, yielded only end-to-end transcripts 
on a consistent basis. Thus the tk (p 1) and gB (py) templates gave no 
discernible transcripts (figure 4, lanes 3 and 5 respectively). The 
VP5 (py) template gave only low yields of the 1.1 kbp RNA (figure 4, 
lane 6). 
Repeating this experiment with a new preparation of extracts 
from uninfected cells made by the Dignam method yielded results 
consistent with the previous experiment (figure 5). The a promoter 
ICPO once again yielded a prominent specific transcript of 1.4 kbp. 
(figure 5, lanes 2 and 7). Promoters of all other kinetic classes failed 
to yield any specific RNA products (figure 5, lanes 3, 4, 6, 8 and 9), 
including the VP5 promoter (figure 5, lane 5). 
As demonstrated from the preceding experiments illustrated 
m figures 4 and 5, promoters of the p and py classes supported little 
or no transcription in in vitro systems in the absence of HSV-1 a 
products. This is consistent with what is known about the 
requirements for herpes virus replication in vivo. Logically, the next 
step would be to prepare nuclear extracts which contained a 
proteins. 
B. Transcription With Infected Cell Extracts 
The simplest and most direct method of enriching a nuclear 
extract with early HS V -1 proteins is to prepare the extracts from 
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I II pBR322 !CPO VP5(~y) III pBR322 
(a) 
Figure 4. In vitro transcription from various HSV-1 promoters using 
a cell free soluble nuclear extract prepared by the Dignam protocol. 
Lanes 1 and 7, bacteriophage 'A DNA cut with HindIII as markers. 
Lanes 2 and 8, pBR322 DNA cut with Alul as markers. HSV-1 DNAs 
used as templates for in vitro transcription and the promoters they 
contained are as follows: Lane 3, gB promoter (2.7 kb fragment Sall/ 
Kpnl fragment of pGTSa2); Lane 4, ICPO promoter (2.9 kb EcoRI/SalI 
fragment of pKSBBO); Lane 5, tk promoter (2.04 kb Pvull fragment 
of pHSV 106 ); Lane 6, VP5 promoter ( 1.7 kb Sall fragment of 
pIM 10 ). End-to-end transcripts are indicated by • and specific tran-
scripts by >. 
~ 
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III 
Figure 5. In vitro transcription of HSV-1 promoters from various 
kinetic classes testing two soluble cell free nuclear extracts 
separately prepared via the Dignam protocol. Lanes 2 through 5 are 
the results of transcriptions performed with an extract at 3.1 µg per 
µl protein concentration. Lanes 6 through 8 are the results of 
transcriptions performed with an extract with a concentration of 1.3 
µg per µl protein. Lanes 1 and 10, bacteriophage A. DNA cut with 
HindIII as a marker. Lanes 2 and 7, ICPO promoter (2.9 kb EcoRI/ 
Sall fragment of pKSBBO). Lanes 3 and 8, tk promoter (2.05 kb 
PvuII fragment of pHSV106). Lanes 4 and 9, gB promoter (2.7 kb 
SalI/KpnI fragment of pGTSa2). Lane 5, VP5 promoter ( 1.7 kb Sall 
fragment of plMlO). Lane 6, gH:L promoter (1.21 kb Kpnl/Pvull 
fragment of pHSV 106 ). 
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prepared and tested for in vitro transcription. They uniformly failed 
to yield detectable specific RN A product. 
Multiple attempts were made to optimize conditions for 
transcription, including substituting other divalent cations (Zn++ and 
Ca++) for magnesium, as well as changing the Mg++ concentration. All 
trials were without success. Representative results of such trials are 
seen in figure 6, lanes 3 and 4. It was interesting to note that there 
was a slight difference in RN A produced under conditions of 1 OmM 
versus 12mM Mg++ (figure 6, all lanes). Despite the lack of readable 
transcripts from transcriptions run using extracts made from 
infected cells, there appeared to be materially greater yield of 
nonspecific RNA (figure 6, lanes 3 and 4). I therefore elected to 
conduct subsequent experiments with p and py promoters with 12 
mM Mg++. 
C. In Vitro Transcriptions With Shapiro Extracts 
While this work was in progress, a new method for making 
HeLa nuclear extracts for cell free transcription systems was 
published (57). The authors asserted extracts produced by this 
protocol yield an increased efficiency of transcription initiation 
ranging from 2 fold to 20 fold over Dignam extracts. The major 
difference between the Shapiro system and the Dignam system 
involved replacing the divalent cations normally found in cell 
extraction buffers, principally Ca++ and Mg++ with a mixture of the 
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Figure 6. In vitro transcription of HSV-1 promoters testing magne-
sium ion concentrations in extracts prepared via the Dignam proto-
col. Extracts from mock infected cells were used in lanes 1, 2, 5, 6, 7, 
8). Extracts from HSV-1 infected cells were used in lanes 3 and 4. 
Lanesl, 3, 5, and 7 were run at 10 mM magnesium. Lanes 2, 4, 6, 
and 8 were run at 12 mM magnesium. End-to-end transcripts are 
indicated by. and specific transcripts by >. 
I 
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the presence of polyamines may more nearly approximate the 
intranuclear environment than do buffers containing divalent 
cations. Additionally, the authors proposed that the substitution of 
polyamines for divalent cations might eliminate the possible 
activation of endogenous DNases within the cell by Mg++ and Ca++. To 
determine if Shapiro extracts might provide better transcription of 
the later gene classes, I prepared uninfected and infected extracts 
according to the published protocol. These were then tested for their 
ability to transcribe from various HSV-1 promoter templates. 
The uninfected Shapiro extracts revealed some evidence of 
discrete RN A bands from the a promoters (figure 7, lanes 2 and 6). 
However, there were no detectable transcripts from promoters of the 
later HSV-1 kinetic classes (figure 7, lanes l, 3, 4 and 5). A 
transcription performed with nuclear extracts made from HSV-1 
infected cells yielded no detectable product (figure 7, lane 7). 
Despite the lack of clearly distinguishable RNA bands, I was 
optimistic that it might still be possible to produce a cell free, soluble 
system capable of transcribing J3 and J3y promoters. The transcription 
done with the VP5 and tk promoters yielded more product RNA 
(albeit degraded) than had been detected on previous assays. I 
thought it was conceivable that a signal from discrete bands might be 
obscured by the heavy degradation, and that it might be possible to 
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Figure 7. In vitro transcription using uninfected (lanes 1-6) and 
infected (lane 9) nuclear extracts prepared by the Shapiro protocol. 
Transcription templates are: Lane 1, gB promoter (2.7 kb Sall/Kpnl 
fragment of pGTSal); Lane 2, ICPO promoter (2.9 kb EcoRI/SalI frag-
ment of pKSBBO); Lane 3, VP5 promoter ( 1.7 kb Sall fragment of 
plMlO); Lane 4, tk promoter (2.05 kb Pvull fragment of pHSV106); 
Lane 5, gD promoter (Smal subfragment of BamHI J); Lane 6, IE4/5 
promoter ( 1.89 BamHI fragment of pRB 122); Lane 7, gH:L promoter 
(1.21 kb Kpnl/pVull fragment of pHSV 106); Lane 8, bacteriophage A. 
DNA digested with HindIII used as a marker. End-to-end transcripts 
indicated by • and specific transcripts by >. 
/ 
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Subsequently, transcription conditions were varied 
experimentally in an attempt to optimize discrete bands of product 
and minimize RNA fragmentation. Additionally, attempts were made 
to isolate any possible sources of exogenous RNase activity. These 
trials included eliminating the RNase inhibitor (Inhibit-Ace) to 
determine if it was effective in decreasing enzymatic RNA 
degradation, and eliminating the creatine phosphokinase and 
creatine phosphate from the reaction mix as possible origins of 
RN ase. Because I was specifically interested in transcription from 
the later promoters, gB (~) was used as the template. 
These attempts were all to no avail. Despite the presence of 
prominent end-to-end transcripts with uninfected extracts, no 
specific RNA products were detected (figure 8, lanes 1, 4 and 6). 
Attempts at transcription using infected cell extracts yielded no 
detectable RNA bands (figure 8, lanes 2, 3, 5 and 7). 
D. In Vitro Transcriptions using vhs-1 Infected Nuclear 
Extracts 
One hypothesis explaining the failure of infected cell 
extracts to yield discrete RN As is that these extracts contain a vffus-
induced nuclease (RNase). It is known that RNase activity is utilized 
by the virus in the process of switching protein synthesis from host 
to viral products (30, 31, 32, 61 ). As previously noted, one of the 
mechanisms utilized by the virus to redirect the host biochemistry 
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Figure 8. In vitro transcription testing various reaction conditions 
with uninfected and infected nuclear extracts prepared by the 
Shapiro protocol. The transcription template in all trials was the gB 
promoter ( 1.7 kb SalI/KpnI fragment of pGTSa2). Lanes 1, 3, 4, and 
6 were run with uninfected extracts. Lanes 2, 5 and 7 were run 
with HSV-1 (KOS strain) infected extracts. Lanes 1 and 2, Shapiro 
reaction conditions. Lane 3, uninfected Dignam extract run under 
Shapiro reaction conditions. Lanes 4 and 5, Shapiro conditions minus 
the RNase inhibitor Inhibit-Ace. Lanes 6 and 7, minus creatine phos-
phokinase and creaatine phosphate. 
I 
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production is the disaggregation of host polyribosomes and 
degradation of host mRN As. This process is mediated by a virion-
specific protein, the VHS protein that is present in the tegument of 
the infecting virion, and therefore is introduced into the host cell 
with initial penetration of the particle. 
The first effort to eliminate the nuclease activity involved the 
use of a vhs 1 mutant. The vhs mutant is derived from the parental 
HSV-1 KOS strain and is defective in the virion-associated host 
protein synthesis shut-off. Cells infected with the vhs 1 mutant m 
particular exhibit prolonged mRNA half-life compared to cells 
infected with the parental KOS strain ( 61 ). 
I decided to attempt to exploit the characteristics of the vhs 1 
mutant and produce an extract from infected cells that might be 
capable of transcribing from By or y class promoters. The initial trial 
was the production of Dignam extracts from HeLa cells infected with 
vhs 1 virus for eight hours. Transcriptions run with the infected 
HeLa extracts revealed no transcription from the infected system. 
As previously noted, the VHS protein is a y product, but it is 
packaged in the tegument of an infecting virion. It is released into 
an infected cell with initial penetration of the virus. However, it is 
known that HSV-1 has a secondary host shut-off function that is 
coded for by a y gene. I thought it possible that the degradation 
observed on transcriptions might be due to this late viral RNase 
rather than the defective VHS protein. I attempted to exploit this 
separation of RNase activities to produce HSV-1 infected extracts 
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capable of in vitro transcription. 
I therefore prepared a Dignam extract with cycloheximide 
reversal and actinomycin D block using vhs 1 mutant virus. The 
antifungal agent cycloheximide is a protein synthesis inhibitor, and 
the antineoplastic drug actinomycin D blocks transcription. The 
protocol developed involved infecting HeLa monolayers with vhs 1 
virus in the presence of cycloheximide. Because the B and y genes 
require a products for protein synthesis (and the secondary v hs 
function is mediated by a y gene), this treatment enriches the cell 
culture in a mRNAs (32). Subsequent reversal of the cycloheximide 
block in the presence of actinomycin D would result in translation of 
a mRN As but prevent transcription of the B or y genes and thereby 
prevent expression of all delayed early and late gene expression, 
including the RNase activity. 
Transcriptions were run utilizing a variety of promoters from 
the various HSV-1 kinetic classes with both uninfected and infected, 
cycloheximide reversed, actinomycin D blocked nuclear extracts. 
Unfortunately, attempts at transcription with these infected nuclear 
extracts did not yield any detectable transcription products. Even 
ICPO and IE 4/5, promoters that had consistently produced specific 
transcripts from uninfected extracts, did not reveal any RNA bands 
(figure 9, lanes 1 through 4 ). As expected, the gH:L promoter did not 
generate discrete RNA (figure 9, lanes 5 and 6). These results can be 
explained by the possibility that the extracts prepared from 
uninfected cells still contained RNase activity. 
Infected 
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Figure 9. In i-ritro transcription utilizing uninfected and vhs 1 in-
fected nuclear extracts prepared via the Dignam protocol. All ex-
tracts were prepared from cycloheximide-reversed, actinomycin D 
blocked cells. Transcription templates were: Lanes 1 and 2, ICPO 
promoter (2.9 kb EcoRl/Sall fragment of pKSBBO); lanes 3 and 4, IE 
4/5 promoter ( 1.89 kb BamHI fragment of pRB122); lanes 5 and 6, 
gH:L promoter ( 1.21 kb KpnI/PvuI I fragment of pHSV 106 ). Lane 7, 
A. DNA cut with HindIII and used as a marker. 
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An alternative explanation for the failure of in vitro 
transcription to generate distinct RN A is that the infected cell 
extracts contain DNase activity that destroyed the templates. It is 
known that HSV-1 codes for at least one alkaline exonuclease ( 17) 
and there may possibly be others. This led to the question of 
whether, in addition to the documented RNase activity present m 
infected cells, there might also be some DN ase activity that destroys 
the templates before detectable products were present. Therefore, a 
series of experiments was devised to address this question. 
The basic approach of these experiments was to incubate DNA 
under transcription reaction conditions for varying increments of 
time from zero to 60 minutes with extracts made of infected and 
mock infected cell nuclei. To differentiate between exonuclease and 
endonuclease activity, intact, covalently closed circular plasmid DNA 
(pBR322) was used in half the trials (figure 10, lanes 4, 6, 8, 10, 12, 
14, 16, and 18). Linear DNA, pBR322 opened at the EcoRI site was 
used in the other half (figure 10, lanes 5, 7, 9, 11, 13, 15, 17, 19). 
The possibility of DNase activity in the nucleic acid purification 
portion of the experiment was ruled out by incubating intact and 
linear pBR322 for 60 minutes in Tris-EDT A buffer and extracting 
with phenol-chloroform-isoamyl alcohol (PCIA) by the usual 
technique. Finally, to test for the presence of nuclease activity in the 
transcription buffer itself, an additional 60 minute incubation of 
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Figure 10. Linear (L) and circular (U) pBR322 incubated with 
Dignam nuclear extracts from HSV-1 (KOS strain) infected (H) or 
uninfected (M) HeLa cells. Plasmid DNA was either left uncut or 
linearized at the EcoRI site and incubated under transcription condi-
tions for the indicated time periods. Following incubation, the DNA 
was extracted with phenol-chloroform-isoamyl alcohol (PCIA), then 
CIA, and purified by ethanol precipitation. The DNA was redis-
solved in Tris-EDT A, pH 7.4, electrophoresed on an agarose gel, and 
visualized by ethidium bromide staining. Lanes 1 and 20, bacteri-
ophage A- DNA restricted with HindIII. Lane 2, uncut pBR322. Lane 
3, pBR322 linearized at the EcoRI site. Lanes 4 through 7, DNA incu-
bated approximately 10 seconds. Lanes 8 through 11, DNA incu-
bated 20 minutes. Lanes 12 through 15, DNA incubated 60 minutes. 
Lanes 16 and 17, DNA plus transcription buffer without added 
nuclear extracts. Lanes 18 and 19, DNA plus transcription buffer 
without added nuclear extracts and PCIA extraction. 
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last trial was not extracted with PCIA. The fate of the DNA was then 
determined by agarose gel electrophoresis (figure 10). 
Interestingly, these tests revealed rapid degeneration of 
circular DNA in all nuclear extract incubations (figure 10, lanes 4, 6, 
8, 10, 12, 14). The linearized plasmid DNA survived degradation to 
some extent in all extracts tested (figure 10, lanes 5, 7, 9, 13, 15). 
While the preceding experiment did not confirm our suspicions 
about a DNase activity destroying linear templates in the 
transcription mix, it effectively closed the door on pursuing another 
alternative that had been under consideration, the use of a circular 
construct as a transcription template. 
Despite repeated attempts at manipulating conditions, virus 
and extracts, I was unsuccessful in achieving the goal of this avenue 
of inquiry--successful in vitro transcription from cell free soluble 
extracts of the VP5 promoter. It was decided, therefore, that further 
elucidation of the viral transcription using nuclear extracts was 
beyond the scope of the current question, and I elected to pursue 
another course of inquiry. 
2. USE OF COMPETITION BINDING ASSAYS TO STUDY VP5 LEAKY-
LATE-DNA BINDING PROTEIN INTERACTIONS 
Shin Chen, working in the Millette laboratory, identified a 
sequence located between -64 and -75 relative to the VP5 cap site 
that is important in transcriptional regulation (figure 11 ). It was 
found that this site bound a cellular factor (LBF) which, by DNasel 
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footprint analysis was found to bind to the sequence 
GGGCCATCTTGAA. This sequence was provisionally designated the 
leaky-late binding sequence (LBS). Deletion or mutation of this 
sequence resulted in decreased expression from the VP5 promoter m 
-1&3 CAAT -4 
1BS 
m-1 I ~ 
'i'c'rrc:c'roGG~~~~~ 
~.AJ:iGG.JYX:X:; 'l"GC:t;-~ 'l'GG'l"C:O:;X;GT H.;Jl.,,JICITJCJJ, '1"GGGCAGOX 
-100 -90 -BO -7'0 -8J 
Fi~ure 11. VP5 promoter identifying the putative leaky 
late binding sequence. 
transient expression assay studies with HSV-1 superinfection (10). 
DNA binding studies carried out in the Millette laboratory revealed 
that this VP5 sequence forms similar complexes with both infected 
or uninfected cell nuclear extracts, yielding two major complexes: 
Complex A, the slower moving band, and Complex B, the faster (10). 
Computer analysis of the HSV-1 DNA sequence identified 
similar sequences in the promoters of the genes for glycoprotein D 
(36), and in the unique long 37 and unique long 46 (UL37 and UL46) 
genes (37). Additionally, a sequence exhibiting high homology to the 
LBS was identified in the coding (internal) portion of the UL37 gene. 
Similar sequences are also found in the human immunodeficiency 
4 1 
virus (HIV) long terminal repeats (LTRs). However, none of these 
sequences are identical to the identified putative LBS (table II). 
I chose to investigate the following question: Does the cellular 
































play a role in the expression of the corresponding genes? With this 
question answered, it would then be possible to do a sequence 
comparison of the promoters that exhibited competition and deduce 
a consensus sequence for the binding of this protein. In addition, 
this analysis would provide clues as to whether similar binding sites 
are involved in the regulation of other viral genes. 
~ 
42 
A series of DNA binding competition experiments was designed 
m which the promoters and other DNA fragments exhibiting 
sequence similarities to the VP5 LBS would be incubated with DNA 
containing the VP5 sequence and nuclear extracts under DNA binding 
conditions. In binding studies, DNA containing the sequence of 
interest is labeled with radioactive phosphorus (32 P) by Klenow fill-
in and subsequently incubated with nuclear extracts under 
conditions that allow DNA binding proteins to adhere to the labeled 
probe. The reaction mix is then electrophoresed on an acrylamide 
gel. In this assay, the DNA that is bound by protein will migrate 
through the acrylamide at a rate that is slower than unbound probe 
DNA. After the gel is dried, it is exposed to x-ray film and the 
radioactively labeled DNA probe will cause a darkening of the film at 
a point corresponding to the location of the DNA or DNA-protein 
complex in the gel. 
In competition experiments unlabeled DNA, the competitor, 1s 
included in large molar excess over the probe in the reaction mix 
with limited amounts of protein. The basic idea is that sequences 
exhibiting homology to the DNA that is bound by a particular protein 
will themselves bind that same protein, i.e., they will compete with 
the probe for the limited DNA binding protein. If competition occurs, 
then a decreased signal from the labeled DNA-protein complex 
results on the autoradiogram. The stronger the competition, the 
weaker the signal from the bound probe, with the strongest 
competitor possible being the unlabeled homologue of the probe 
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DNA. 
The first problem was to design the experiment so that the 
detection of weak competition is possible. Even under optimal 
competitive conditions, i.e., large molar excess of homologous DNA, 
there is often an appreciable signal from the protein-bound probe. It 
therefore can be difficult to detect competition at some level less 
than what would be expected from a labeled homologue. That is, the 
sensitivity of the assay needed to be maximized. It is imperative to 
avoid an excess of protein, or competition will not cause a decreased 
signal from the probe. 
To accomplish this, a series of experiments was carried out in 
which a potential competitor was utilized to define conditions for 
subsequent studies. The glycoprotein D promoter fragment contains 
a sequence homology to eight out of ten bases with the VP5 
promoter sequence of interest. If this segment of the gD promoter 
was bound by the putative leaky-late binding factor, I thought it 
likely that competition would occur, but at some degree less than 
that of an unlabeled VP5 homologue. Therefore, the gD promoter 
was used to define conditions for the competition studies. Detectable 
competition was represented as a slightly fainter signal in complex A, 
and a somewhat greater difference in signal strength at complex B. 
This competition occurred between gD and VP5 under the conditions 
of approximately 0.75 µg protein with a 40-fold molar excess of gD 
DNA. An example of such competition with the gD promoter can be 
seen in figure 12, lane 6 and 7. 
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Figure 12. Competition binding of labeled VP5 promoter versus 
unlabeled DNA fragments. DNA binding competition was carried out 
with 1.8 µg of protein of infected nuclear extracts as described. A, B, 
and P, complexes A, B and free probe, respectively. Lanes 1 and 2, 
free probe. Lane 3, labeled VPS promoter without competitor. Lanes 
4 and 5, 40-fold and 60-fold molar excesses of unlabeled VPS pro-
moter. Lanes 6 and 7, 40-fold and 60-f old molar excesses of glycop-
rotein D promoter. Lane 8, 40-fold molar excess of HIV promoter ( + 1 
to -423). Lanes 9 and 10, 40-fold and 60-fold molar excesss of HIV 
promoter ( + 1 to -167). 
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Competition studies were subsequently performed with 0.75 µg 
protein in which all the above-mentioned sequences were tested 
against the VP5 LBS. As expected, the degree of competition 
declined with decreasing homology between the LBS and the 
competing DNA. In an attempt to detect weak competition, the 
quantity of competitor excess was titrated against the LBS and DNA 
binding protein in the competition mix. 
The initial experiment involved running competition studies 
with labeled VP5 probe versus unlabeled homologue as a positive 
control. Additionally, DNA containing a promoter for a gene coding 
for a trans-acting factor located in the 3' long terminal repeat (LTR) 
of the human immunodeficiency virus (HIV) was included. This HIV 
promoter exhibited a region of homology with only the terminal 7 of 
12 bases in the proposed LBS (table II). 
Competition was detectable in all cases, although it varied with 
respect to the strength of competition and with respect to which of 
the two major complexes, A or B, was competed against more 
strongly. As expected, the unlabeled VP5 homologue exhibited the 
strongest competition, (figure 12, lanes 4 and 5) but with the 
stronger competition occurring against the upper band, complex A. 
The glycoprotein D promoter competed as expected against the VP5 
fragment, but with a stronger signal reduction occurring in the faster 
moving complex B (figure 12, lanes 6 and 7). 
The HIV fragments also exhibited competition, although it was 
somewhat weaker than the competition exhibited by the other 
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fragments. This was not unexpected because the HIV sequence 
exhibits homology with only the terminal seven of 12 bases of the 
putative LBS. Of interest is the difference in competition exhibited 
by the two HIV fragments. Both of these pieces of DNA originate 
from the same portion of the viral genome, the only difference 
between them is that the HIV promoter fragment in figure 12, lane 8 
contains 256 bases upstream from the cap site that are not present 
in the other HIV fragment run in lanes 9 and 10 in figure 12, i.e., + 1 
to -423 versus +1 to -167. 
To verify the competition between the VP5 fragment and the 
HIV fragment, another test was run utilizing a 100-fold excess of the 
small ( -167 to + 1) HIV promoter (figure 13, lane 4) against an 80-
fold excess of the unlabeled VP5 competitor (figure 13, lane 3). As 
demonstrated previously, there was stronger competition against 
complex A from the VP5 fragment. The same phenomenon is 
exhibited with respect to the HIV fragment (figure 13, lanes 3 and 
4). 
Computer search had revealed the presence of potential 
homologueues of the VP5 LBS in other HSV-1 genes. To determine if 
these too bound LBF, further competition binding studies were 
performed to assess whether these sequences bound the same 
cellular factor bound by VP5 LBS. 
As seen in previous experiments, the HIV sequences competed 
with the VP5 fragment, although weakly (figure 14, lanes 4 and 5). 
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Figure 13. Competition binding of labeled VPS promoter versus 
unlabeled DNA fragments. DNA binding competitions were carried 
out with 1.8 µg of protein infected nuclear extracts as described. A, B 
and P indicate complexes A, B and free probe respectively. Lane 1, 
free probe. Lane 2, labeled VPS promoter without competitor. Lane 
3, 80-fold molar excess of unlabeled VPS promoter. Lane 4, 100-fold 
excess of HIV promoter ( + 1 to -167). 
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Figure 14. Competition binding of labeled VPS promoter versus 
unlabeled DNA fragments. DNA binding competition was carried out 
with 1.8 µg of protein of infected nuclear extracts as described. A, B 
and P indicate complexes A, B and free probe respectively. Lane 1, 
free probe. Lane 2, labeled VPS promoter without competitor. Lane 
3, 40-fold molar excess of VPS homolog. Lane 4, 80-fold molar ex-
cess of HIV ( + 1 to -423 ). Lane 5, 80-fold molar excess of HIV ( + 1 to -
167). Lane 6, 100-fold molar excess of UL37 (+203 to -415). Lane 7, 
100-f old molar excess of UL37 coding region ( + 333 to + 1019 ). Lane 
8, 100-fold molar excess of UL46 promoter ( + 118 to -161 ). Lane 9, 
100-fold molar excess gB promoter ( + 134 to -249 ). 
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the internal UL37 sequence exhibiting homology to the VP5 coding 
sequence exhibited stronger competition than did the promoter 
sequence (figure 14, lanes 6 and 7). Both UL46 and glycoprotein B 
exhibited some weak competition, more remarkably against complex 
B than against complex A (figure 14, lanes 8 and 9). 
In general, the HSV-1 promoters appeared to compete more 
strongly against complex B, while the HIV, though weakly 
competitive, exhibited more striking results against the larger 
complex A .. 
CHAPTER IV 
CONCLUSIONS 
1. IN VITRO TRANSCRIPTION 
The herpes simplex virus VP5 promoter has, so far, been 
difficult to transcribe in in vitro transcription systems. Repeated 
attempts at manipulating experimental conditions and trials with 
different strains of virus were unsuccessful. While it is not possible 
to definitely ascribe this lack of success to any one attribute of viral 
physiology, it is possible to hypothesize about the negative results. 
Herpes simplex virus has a well documented, though poorly 
understood system by which host protein synthesis is redirected to 
the production of viral progeny (30, 31, 32, 50, 60). This system is 
known to degrade host mRNA, and it has been hypothesized that this 
RNA destruction is necessary for the efficient switching of 
transcription between the temporal classes. The persistent presence 
of what is construed to be RNase activity in the transcription mixture 
prepared from infected extracts is the most obvious reason for the 
lack of readable transcripts. Multiple attempts that were made to 
circumvent this problem and all proved unsuccessful. 
Another cause for lack of readable transcripts originating from 
late promoters may be the failure of the template itself to survive 
long in the transcription mix from infected cells. It is interesting that 
5 1 
the surviving templates in the incubation experiments (figure 10) 
were linear, while the circular plasmids were degraded. An 
endonuclease activity is the obvious explanation for the failure of 
intact circular DNA to persist in the transcription mix. However, the 
possible reasons for the preferential degradation of the formerly 
circular template over a linearized template incubated under the 
same circumstances remains elusive. 
The presence of high molecular weight DNA at the origin in 
figure 10, lanes 4 and 6 is interesting. This could possibly indicate 
the presence of a DNA binding protein in the nuclear extract. 
Incubation with nuclear extract for a few seconds conceivably could 
permit protein binding. 
The reasons for the failure of the Shapiro extracts to produce 
stable transcripts is not understood. There was one major difference 
between our protocol and the one published by the author. Because 
it was necessary to make infected extracts, our cells were grown in a 
monolayer culture in roller bottles. The published protocol specified 
the use of cells grown in suspension in spinner cultures. It may be 
that the physical and biochemical differences between the two HeLa 
cell lines were significant contributors to the failure to produce 
stable mRNAs by in vitro transcription. 
2. DNA BINDING COMPETITION STUDIES 
The gel mobility assays were somewhat more successful. As 
demonstrated in figures 13, 14, and 15, competition occurred in all 
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cases, although at different strengths. In general, the herpes 
promoters exhibited a greater level of competition than did the HIV-
1 promoter, although the gB promoter was competitive only at a very 
great (100 fold) molar excess. 
It was interesting to note that were was a difference in 
competition between the HIV preparations. In some cases the HIV 
DNA competed only weakly (figure 12, lanes 8, 9 and 10; figure 14, 
lanes 4 and 5). However, in cases in which competition was 
observed, the promoter from pU3RIII competed more strongly than 
pU3RIII-167. It is notable that he larger plasmid, pU3RIII, contains 
256 bases upstream that are not present in pU3RIII-167. Analysis 
of this sequence reveals three areas of partial homology to the 
putative LBS located at -351, -398 and -411 that are not carried by 
the smaller plasmid (figure 16). Until it is demonstrated otherwise, 
these regions of possible LBF binding must be considered potentially 
responsible for the different levels of competition exhibited by the 
HIV fragments. 
It is interesting to note the differences in competition between 
the UL37 internal coding sequence and the UL37 promoter sequence. 
The internal sequence exhibits ten base pairs of homology with the 
VP5 LBS. In contrast, the promoter sequence exhibits three base 
pairs that are not homologous at positions #8, #10 and #12 of the 
VP5 LBS (table 3). The difference in competition between these two 
fragments of UL37 suggests that these three bases are important in 












-159 LBS homology 
CTGATATCGAGCTTGCTACAAGGGACITICGCfGGGACTITC'CAGGGAGGCGfGGCCTG 
GCGGGACTGGGGAGTGGCGAGC'CCTCAGATC'CTGCATATAAGCAGCfGCI Ill IGCCTGfACT 
Fi~ure 15. HIV sequence from -423 to +1 of the 3' long 
terminal repeat. 
DNA are very close to the same size (686 base pairs for the internal 
sequence versus 616 base pairs for the coding sequence). Thus the 
possibility of nonspecific DNA binding contributing to the difference 
in competition is not great. 
Based on the above data, the following consensus is proposed 
for the LBS: GGGCCATNTTGA (table III). 
After this work was completed, several authors reported 
successful isolation of a protein that binds to a similar sequences m 
several different genes (45, 50, 56, 58).. This protein, alternately 
named YYl, NF-El, and NF-B among others, has been reported to 
function as a transcription activator in the context of ribosomal 
protein promoters (56), and as a transcriptional repressor when 
binding the human immunoglobulin x:3' enhancer and the human 
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TABLE III 
VP5 IG G G c CIAITICITITIGIAIA 
G G G c c A T 
t ~rlcJJ B I c c A T g a T G A A 
UL46 G G G c c A T g g 
UL37 - Promoter G c c A T t T 
UL37 - Codin G c c A T c T T Gr: 
HIV T c T T G AIA 
Table 3. The proposed binding sequence of fragments with 
homology to the LBS. Upper case letters and shading indicate 
base pair homology. Lower case letters and unshaded areas 
indicate lack of homology. 
immunoglobulin heavy chain µEl site (45). Subsequent work carried 
out by Lisa Mills in the Millette lab has demonstrated that the 
cellular protein LBF is the same molecule as transcription factor YYl 
( 41) and that this protein plays a role in the HSV-1 py genes by viral 
fact)ors. 
3. SUMMARY 
In summary, I have presented several lines of experimental 
investigation that have indicated that genes of the p, py, and y kinetic 
classes of herpes simplex virus type 1 are resistant to analysis by in 
vitro transcription. HSV-1 genes of the a class require only the viral 
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protein a TIF in addition to cellular transcription factors for 
activation. Because aTIF is packaged in the tegument of the infecting 
virion, it is released into the host cell with initial viral penetration. 
Therefore, it is present at the onset of the transcription of a genes. 
However, promoters of the later genes require a gene products. 
Attempts at preparing nuclear extracts capable of transcribing these 
later promoters in general, and from ~y promoters in particular, were 
uniformly unsuccessful. This failure to generate specific RNA may be 
attributable to persistent RNases in the nuclear extracts which are 
coded for by the viral DNA and are therefore endogenous to the 
virus. Further attempts at in vitro transcription will necessarily 
depend upon the successful repression of these virus specific 
enzymatic activities. 
DNA binding competition studies revealed that an assortment 
of herpes simplex virus type 1 genes exhibiting partial homology to 
the LBS of the HSV-1 VP5 promoter competed for the same protein 
factor. Additionally, a short fragment of human immunodeficiency 
virus from the 3' long terminal repeat containing a seven base pair 
homology exhibited weak competition. Based on this work a 
consensus sequence was proposed. Subsequent work in the Millette 
laboratory demonstrated that this sequence binds a ubiquitous 
cellular transcription factor, alternately named YYl. 
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